Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting
Scott F. Huntington, Justin T. Puckett, Beenish S. Manzoor, Nnadozie Emechebe, Sophia S. Li, Sachin Kamal-Bahl, Carolina Reyes, Holly Budlong, Jalpa A. Doshi · 2026
Read Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting by Scott F. Huntington, Justin T. Puckett, Beenish S. Manzoor, Nnadozie Emechebe, Sophia S. Li, Sachin Kamal-Bahl, Carolina Reyes, Holly Budlong, Jalpa A. Doshi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13297127.txt.
Description
Scott F. Huntington and colleagues compare first treatments for chronic lymphocytic leukaemia in older Medicare patients in a 2026 real-world study. Trial results may not carry over to everyday older patients, who often carry other illnesses. United States Medicare records were used to compare venetoclax-based therapy, BTK-inhibitor therapy, and other regimens.
Patients starting venetoclax-based treatment lived longer than those in the other groups. They were also less likely to need a further treatment later. Targeted oral drugs have largely replaced older chemotherapy for this disease, yet head-to-head everyday evidence has been scarce. The findings give doctors and researchers practical information for choosing first therapy in older adults.
Catalog record
| CREATOR | Scott F. Huntington, Justin T. Puckett, Beenish S. Manzoor, Nnadozie Emechebe, Sophia S. Li, Sachin Kamal-Bahl, Carolina Reyes, Holly Budlong, Jalpa A. Doshi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |